MindWalk Holdings Corp. Q3 2026 Earnings Call Summary

Core Insights - The company achieved a third consecutive quarter of year-over-year revenue growth, driven by a strategic pivot towards the high-demand U.S. AI-driven discovery market [1] - The company signed its first one-year enterprise Lens AI platform contract, transitioning from one-off project fees to predictable, monthly recurring revenue [1] Technology and Innovation - The Lens AI platform is differentiated by focusing on the 'invariant functional layer' of biology (HIFT) rather than surface sequence similarity, enabling the detection of IP risks and functional adjacencies that competitors may overlook [1] - The HIFT approach was validated by identifying a single conserved functional feature across over 2,000 influenza sequences, representing a potential target for a universal immunogen [1] - The dengue program was advanced by targeting a single conserved epitope present in all four serotypes, aiming to address the historical 'antibody-dependent enhancement' failure mode of previous vaccines [1] - The B Cell LAMA platform was launched to address the 'chain-pairing problem' in multispecific antibody development by utilizing naturally matured llama nanobodies that lack light chains [1] Strategic Focus - The company divested its European operations to concentrate capital and resources on North American commercial growth and Canadian laboratory capabilities [1]